Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

What is CJC-1295 with DAC?

CJC-1295 with DAC is a GHRH analogue bearing a Drug Affinity Complex that extends its half-life. This page covers its identifiers, its GH-IGF-1 axis target, and what the published literature and trial records actually re

peptides-pro Editorial

CJC-1295 with DAC is a growth hormone-releasing hormone (GHRH) analogue modified with a Drug Affinity Complex (DAC), placing it in the GHRH-analogue class of agents that act on the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis. It is listed in the clinical and self-administration literature alongside sermorelin, tesamorelin, and CJC-1295 without DAC as one of the GHRH analogues most commonly encountered, and alongside growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin, and ipamorelin [1]. The evidence block supplied for this page does not give a sequence, molecular formula, or molecular weight for the compound, so none are stated here.

The work on this compound centres on the GHRH receptor and the somatotropic axis it drives — the receptor family through which GHRH analogues signal to promote endogenous growth hormone release.

Research Studies

CJC-1295 with DAC and its position among GH-IGF-1 axis peptides

A review of performance-enhancing peptides that modulate the GH-IGF-1 axis describes CJC-1295 with DAC as one of the GHRH analogues encountered in clinical practice and in online self-administration protocols, grouping it with sermorelin, tesamorelin, and CJC-1295 without DAC [1]. The same review places GHRH analogues in a broader field that also includes growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin), the GH fragment AOD9604 (hGH 176-191), and IGF-1 analogues [1]. That framing is descriptive of the market and the clinical encounter; it is not a statement of efficacy for any individual agent.

CJC-1295 with DAC and the GH-IGF-1 axis in the peptide therapeutics literature

Reviews of peptide therapeutics in gerontology describe the class as targeting hallmarks of aging that include hormonal decline, metabolic dysfunction, tissue repair impairment, and telomere attrition, and they assess the evidence base and safety profiles of peptides with demonstrated or potential applications in healthy aging and age-related conditions [3]. GHRH analogues sit within that hormonal-decline category by virtue of their axis target. The gerontology review is a narrative synthesis of mechanisms, applications, evidence, and safety; it does not report a CJC-1295-with-DAC-specific outcome in the material available here.

CJC-1295 with DAC and the HIV-associated visceral obesity trial

The clearest interventional record in the evidence block is a multicentre, randomized, placebo-controlled, double-blind Phase 2 study of CJC 1295 in patients with HIV-associated visceral obesity [6]. Participants were treated for a total of 12 weeks, with a 6-week follow-up period after treatment ended, and were randomly assigned to low-dose CJC 1295, high-dose CJC 1295, or placebo [6]. The stated objective was to assess and compare efficacy, pharmacokinetics, safety, and tolerability in that population [6]. Note the population: adults with HIV-associated visceral obesity, not healthy volunteers and not athletes. The registry record describes the design and objective; it does not supply outcome results in the material provided.

CJC-1295 with DAC and the purity of research-grade material

An evaluation of research-grade peptides marketed directly to consumers used a large, publicly available independent testing dataset to assess purity, measured abundance, and endotoxin burden, and to compare cost against compounded and FDA-approved alternatives [2]. The study frames the context as a rapidly expanding drug class with a parallel, largely unregulated gray market selling preparations directly to consumers for self-administration, with purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement [2]. This finding concerns the category of gray-market research peptides as tested, and it is relevant to any compound in that category, including GHRH analogues.

CJC-1295 with DAC and the regulatory status of unapproved peptides

A review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance describes peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and notes that use in sports medicine is expanding on patient demand for accelerated injury recovery and performance enhancement [4][5]. The same work contrasts peptide drugs that have undergone a rigorous approval process evaluating safety and efficacy with a parallel gray market of unapproved compounds operating largely outside regulatory oversight [4][5]. CJC-1295 with DAC falls on the unapproved side of that division in the material available here.

CJC-1295 with DAC and the evidence gap in sports medicine

Structured reviews of injectable peptides in sports medicine report that clinical adoption has outpaced high-quality evidence and regulatory consensus, and set out to summarise contemporary human and translational evidence for musculoskeletal recovery, tissue repair, and performance enhancement [8]. Related work reports that the peptide supplement market has grown rapidly on marketing claims of enhanced performance and accelerated recovery, and that these products are often perceived as low risk despite the absence of efficacy or safety data [7]. A critical review of peptide and peptide-analogue use in recreational and professional sport and bodybuilding describes a shift from anabolic-androgenic steroids toward peptides marketed as more selective and ostensibly safer alternatives, a group that includes growth hormone secretagogues such as ipamorelin and growth hormone-related peptides [10]. These are category-level findings about the state of the evidence, not compound-specific results.

CJC-1295 with DAC and the comparison of approved versus unapproved agents

The table below sets out how the evidence block distinguishes the two regulatory tracks. It compares categories, not individual products, and no efficacy comparison between CJC-1295 with DAC and any approved drug is made here because the evidence block does not supply one.

DimensionApproved peptide drugsUnapproved / gray-market peptides
Regulatory reviewRigorous approval process evaluating safety and efficacy [4][5]Largely outside regulatory oversight [4][5]
Marketing channelApproved therapeutic supplyMarketed direct to patients and consumers [4][5]
Testing dataCovered by approval requirementsIndependent dataset assessed purity, measured abundance, and endotoxin burden [2]
Evidence baseSafety and efficacy evaluated pre-approval [4][5]Clinical adoption has outpaced high-quality evidence and regulatory consensus [8]

CJC-1295 with DAC and the limits of the available record

Across the sources in the evidence block, CJC-1295 with DAC appears as a named member of the GHRH-analogue class [1] and as the subject of a registered Phase 2 trial in a specific clinical population [6]. The remaining sources address the peptide field at the level of class, market, regulation, and evidence quality [2][3][4][5][7][8][10]. No source provided here reports a receptor-binding constant, a pharmacokinetic parameter, or a clinical outcome specific to CJC-1295 with DAC, and none is asserted on this page. Where a reader encounters claims about this compound that go beyond class membership and trial registration, those claims are not supported by the material assembled here.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp